AbCellera Biologics (ABCL) Non-Current Assets (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Non-Current Assets came in at $642.5 million in Q1 2026, up 10.93% YoY from $579.2 million in Q1 2025, and up 2.19% on a QoQ basis from $628.7 million in Q4 2025.
AbCellera Biologics (ABCL) Non-Current Assets (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Non-Current Assets data on file, last reported at $642.5 million in Q1 2026.
- Quarterly Non-Current Assets rose 10.93% year-over-year to $642.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $642.5 million (up 10.93% YoY) and the FY2025 annual result came in at $628.7 million, up 3.21% from the prior year.
- Non-Current Assets improved to $642.5 million in Q1 2026, from $628.7 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $660.9 million in Q3 2025 to a low of $417.9 million in Q1 2022.
- A 5-year average of $587.2 million and a median of $609.2 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets surged 89.49% — and 2025, when it dropped 10.77%.
- Tracing ABCL's Non-Current Assets over 5 years: stood at $515.4 million in 2022, then climbed by 19.54% to $616.1 million in 2023, then slipped by 1.12% to $609.2 million in 2024, then climbed by 3.21% to $628.7 million in 2025, then increased by 2.19% to $642.5 million in 2026.
- The last three Non-Current Assets figures came in at $642.5 million (Q1 2026), $628.7 million (Q4 2025), and $660.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | 628.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 628.35 Mn |
| Mar 31, 2026 | 642.52 Mn |
| Dec 31, 2025 | 628.72 Mn |
| Sep 30, 2025 | 660.85 Mn |
| Jun 30, 2025 | 659.92 Mn |
| Mar 31, 2025 | 579.23 Mn |
| Dec 31, 2024 | 609.18 Mn |
| Sep 30, 2024 | 649.95 Mn |
| Jun 30, 2024 | 640.93 Mn |
| Mar 31, 2024 | 649.15 Mn |
| Dec 31, 2023 | 616.11 Mn |
| Sep 30, 2023 | 592.67 Mn |
| Jun 30, 2023 | 606.43 Mn |
| Mar 31, 2023 | 557.27 Mn |
| Dec 31, 2022 | 515.42 Mn |
| Sep 30, 2022 | 506.74 Mn |
| Jun 30, 2022 | 449.83 Mn |
| Mar 31, 2022 | 417.91 Mn |
| Dec 31, 2021 | 388.77 Mn |
| Sep 30, 2021 | 368.99 Mn |